Key Highlights

● Profusa shares have fallen sharply, most recently closing at $7.57, down 44.22%, after the company disclosed a non-binding term sheet to acquire a privately held diagnostics and toxicology testing business.

● A 1-for-4 Reverse Stock Split took effect at 12:01 a.m. Eastern on August 17, 2026, cutting outstanding shares from about 2.42 million to roughly 605,726.

● The company reported a Q1 2026 net loss of about $3.46 million, cash on hand of only about $375,000, and negative stockholders' Equity of roughly $28.2 million.

● The Acquisition term sheet is explicitly non-binding, with no assurance the deal closes on the outlined terms or without further Shareholder dilution.

Profusa (NASDAQ:PFSA), a Berkeley-based digital-health company developing injectable, tissue-integrated biosensors for continuous biochemical monitoring, has been one of the most volatile names on the U.S. market this summer. The stock landed on watch lists of notable decliners after a sharp mid-August pullback that followed a string of corporate actions, including a reverse stock split and a newly announced acquisition plan. The moves have left the shares whipsawing on heavy Volume and low absolute price, a combination that tends to magnify percentage swings in either direction.

The most identifiable recent trigger for downside came when the stock fell sharply, most recently closing at $7.57, down 44.22%, after Profusa disclosed a non-binding term sheet to acquire a privately held, commercial-stage diagnostics and toxicology testing company. Although management framed the potential deal as a route to near-term revenue, traders reacted to the risks that typically accompany such transactions for a cash-strapped micro-cap: the prospect of issuing new shares to fund a purchase, uncertain financing, and integration challenges. Critically, the term sheet is explicitly non-binding, meaning there is no assurance the transaction will close on the outlined terms, or at all. That uncertainty, layered on top of an already fragile balance sheet, appears to have driven the selling.

The reverse split backdrop

Compounding the picture is Profusa's repeated use of reverse stock splits. On 13 August 2026 the company announced a 1-for-4 reverse split that took effect at 12:01 a.m. Eastern on 17 August 2026, with shares resuming trading under the same PFSA ticker and a new CUSIP. The action reduced outstanding shares from roughly 2.42 million to about 605,726, while authorized shares remained at 601 million. The company did not spell out a detailed rationale in the announcement, but reverse splits of this kind are commonly used to lift a low per-share price and support continued listing compliance on Nasdaq, which maintains minimum bid-price requirements.

Coverage during the month noted this was among multiple reverse splits Profusa has executed in 2026, a pattern that itself tends to unsettle investors. Frequent consolidations can signal persistent downward pressure on the share price and raise concerns about ongoing dilution, because a large gap between authorized and outstanding shares leaves substantial room to issue new stock. For a company with limited cash, that overhang is a recurring source of anxiety for existing holders, even when individual corporate actions are routine on their face.

The financial picture

Profusa's fundamentals help explain why the market reacts so violently to news. Based on its most recently reported quarterly results for the first quarter of 2026, the company posted a net loss of roughly $3.46 million and burned about $2.6 million in operating cash. Most striking is the Liquidity position: cash on hand was reported at only about $375,000, and the company carried negative stockholders' equity of roughly $28.2 million. Those figures point to a Business that has been spending well in excess of the cash it generates and that has historically leaned on external financing to keep operating.

Against that backdrop, the logic of pursuing a revenue-generating diagnostics and toxicology target is straightforward: an operating, cash-producing business could diversify Profusa beyond its pre-commercial biosensor platform and provide a clearer path to top-line growth. But the same weak Balance Sheet that makes a deal attractive also makes it hard to finance without diluting shareholders or taking on obligations, which is precisely the tension the market is pricing. Separately, reporting during the period referenced a July 2026 option agreement involving G3 Vision Labs and ongoing management transitions, additional signs that the company is actively reshaping its strategy.

Why investors are concerned

The core worry is Solvency and dilution rather than any single piece of bad news. With minimal cash, sustained losses, and negative equity, Profusa depends on its ability to raise capital, and each financing or share-related action reminds holders that their stake can be diluted. The non-binding nature of the acquisition adds another layer: investors are being asked to weigh a potential strategic benefit that may never materialize against the near-certainty that funding any deal would require fresh capital. Low-float, low-price stocks like PFSA also attract momentum-driven trading, which can push shares up sharply on optimism and then reverse just as quickly, exactly the kind of round trip that lands a name on a biggest-losers screen.

It is worth distinguishing confirmed facts from interpretation. The confirmed catalysts are the 1-for-4 reverse split effective 17 August and the 20 August disclosure of a non-binding acquisition term sheet, which coincided with a roughly 18% single-day decline. The broader narrative, that dilution fears and balance-sheet stress are driving persistent volatility, is a reasonable reading of the price action and the company's disclosures, but the precise mix of factors behind any given day's move in such a thinly traded stock cannot be pinned down with certainty.

What to watch next

The most important near-term item is whether the diagnostics and toxicology acquisition advances from a non-binding term sheet to a definitive agreement, and if so, how it is financed. Terms that rely heavily on new equity would likely weigh on the stock, while a structure that adds Revenue with limited dilution could be received differently. Investors will also watch for any Capital raise, updated cash runway, or going-concern language in Profusa's next quarterly filing, along with confirmation that the company remains in compliance with Nasdaq's listing standards following the reverse split.

Beyond deal mechanics, the durability of Profusa's core biosensor program and any commercialization or Partnership progress remain relevant to the longer-term thesis. For now, PFSA fits the profile of a speculative micro-cap: a small company with a differentiated technology idea but severe financial constraints, whose share price is being driven as much by corporate actions and financing dynamics as by operating results. That profile carries elevated risk, and the recent crash reflects how quickly sentiment can turn when a fragile balance sheet meets uncertain strategic news.